| Active Not Recruiting | A Study of Avoralstat In Participants With Diabetic Macular Edema Diabetic Macular Edema (DME) | Phase 1 | 2025-10-02 |
| Recruiting | A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 Netherton Syndrome | Phase 1 | 2024-09-26 |
| Completed | Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | 2023-10-24 |
| Terminated | Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | 2023-01-18 |
| Active Not Recruiting | Berotralstat Treatment in Children With Hereditary Angioedema Hereditary Angioedema, Pediatric | Phase 3 | 2022-10-25 |
| Terminated | Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy | Phase 2 | 2022-02-18 |
| Terminated | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Respons Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | 2021-12-06 |
| Terminated | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Com Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | 2021-10-26 |
| Enrolling By Invitation | Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies Hereditary Angioedema, HAE | Phase 3 | 2021-07-23 |
| Terminated | A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 2 | 2020-12-18 |
| Terminated | A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID COVID-19, Yellow Fever | Phase 1 | 2020-04-09 |
| Completed | First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH Paroxysmal Nocturnal Hemoglobinuria | Phase 1 / Phase 2 | 2020-03-03 |
| Completed | Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Hereditary Angioedema, HAE | Phase 3 | 2018-12-27 |
| Completed | A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 Marburg Virus Disease | Phase 1 | 2018-12-10 |
| Completed | A Long Term Safety Study of BCX7353 in Hereditary Angioedema Hereditary Angioedema, HAE, Prophylaxis | Phase 2 / Phase 3 | 2018-02-16 |
| Completed | Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE Hereditary Angioedema, HAE | Phase 3 | 2018-02-06 |
| Completed | Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema Hereditary Angioedema (HAE) | Phase 2 | 2017-07-31 |
| Completed | A Relative Bioavailability Study of Two Formulations of BCX7353 Hereditary Angioedema | Phase 1 | 2017-02-27 |
| Completed | A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions Hereditary Angioedema | Phase 1 | 2017-02-17 |
| Completed | Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema Hereditary Angioedema (HAE) | Phase 2 | 2016-08-01 |
| Completed | An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Hereditary Angioedema | Phase 1 | 2016-03-01 |
| Terminated | Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema Hereditary Angioedema, HAE | Phase 3 | 2015-12-01 |
| Completed | Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza Influenza | Phase 3 | 2015-12-01 |
| Completed | First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Hereditary Angioedema | Phase 1 | 2015-05-01 |
| Completed | Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influ Influenza | Phase 3 | 2015-03-11 |
| Completed | 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks Hereditary Angioedema, HAE | Phase 2 / Phase 3 | 2014-12-17 |
| Completed | A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430 Filovirus Infections, Ebola Virus Infection | Phase 1 | 2014-12-01 |
| Completed | Study to Determine How BCX4161 is Metabolized and Eliminated by the Body Hereditary Angioedema | Phase 1 | 2014-08-01 |
| Completed | A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 Hereditary Angioedema | Phase 1 | 2014-04-01 |
| Completed | Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE Hereditary Angioedema | Phase 2 | 2013-11-01 |
| Completed | A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Gout, Hyperuricemia, Arthritis | Phase 2 | 2011-09-01 |
| Completed | Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol Gout, Hyperuricemia, Arthritis | Phase 2 | 2010-12-01 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza. Influenza | Phase 3 | 2010-10-01 |
| Completed | Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subje Gout | Phase 2 | 2010-05-01 |
| Terminated | A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standa Cough, Sore Throat, Nasal Congestion | Phase 3 | 2009-11-01 |
| Completed | Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Seasonal Influenza, Cough, Sore Throat | Phase 3 | 2009-10-01 |
| Completed | Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout Gout | Phase 2 | 2009-09-01 |
| Completed | A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramu Acute, Uncomplicated Human Influenza | Phase 2 | 2008-07-01 |
| Completed | Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) Chronic Lymphocytic Leukemia (CLL) | Phase 2 | 2008-03-01 |
| Terminated | Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza Influenza | Phase 3 | 2008-01-01 |
| Completed | Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening In Influenza | Phase 2 | 2007-07-01 |
| Completed | Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Cutaneous T-cell Lymphoma (CTCL), | Phase 2 | 2007-07-01 |
| Completed | Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza. Influenza | Phase 2 | 2007-01-01 |
| Terminated | Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymp Leukemia, Lymphoma | Phase 2 | 2006-07-01 |
| Completed | Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukem Leukemia, Lymphocytic, Chronic | Phase 2 | 2005-06-01 |
| Completed | Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stag Lymphoma | Phase 1 | 2004-11-01 |
| Completed | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2004-09-01 |
| Completed | Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia Leukemia, T-Cell | Phase 2 | 2004-03-01 |
| Completed | BCX-1777 in Treating Patients With Refractory Cancer Cancer | Phase 1 | 2003-04-01 |
| Completed | BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma Lymphoma | Phase 1 / Phase 2 | 2003-02-01 |
| Completed | Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas Leukemia, Lymphocytic, Lymphoma | Phase 1 / Phase 2 | 2001-08-01 |
| Completed | A Study of Peldesine (BCX-34) in HIV-Infected Patients HIV Infections | Phase 1 | — |
| Approved For Marketing | Oral Berotralstat Expanded Access Program Hereditary Angioedema, HAE, Prophylaxis | — | — |
| Withdrawn | Intramuscular Peramivir for the Treatment of Uncomplicated Influenza Influenza | Phase 3 | — |